<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">vedomostiregmed</journal-id><journal-title-group><journal-title xml:lang="ru">Регуляторные исследования и экспертиза лекарственных средств</journal-title><trans-title-group xml:lang="en"><trans-title>Regulatory Research and Medicine Evaluation</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">3034-3062</issn><issn pub-type="epub">3034-3453</issn><publisher><publisher-name>Federal State Budgetary Institution ‘Scientific Centre for Expert Evaluation of Medicinal Products’ of the Ministry of Health of the Russian Federation (FSBI ‘SCEEMP’)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.30895/1991-2919-2022-12-1-8-23</article-id><article-id custom-type="elpub" pub-id-type="custom">vedomostiregmed-402</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Главная тема: Спектральные методы анализа в экспертизе лекарственных средств</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>MAIN TOPIC: SPECTROSCOPIC METHODS USED IN MEDICINE EVALUATION</subject></subj-group></article-categories><title-group><article-title>Метод ЯМР в отечественной и зарубежных фармакопеях для оценки качества лекарственных средств</article-title><trans-title-group xml:lang="en"><trans-title>NMR as Used in the Russian and Foreign Pharmacopoeias for Quality Control of Medicinal Products</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1310-4477</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Моисеев</surname><given-names>С. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Moiseev</surname><given-names>S. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Моисеев Сергей Владимирович, кандидат химических наук, доцент</p><p>Петровский б-р, д. 8, стр. 2, Москва, 127051</p></bio><bio xml:lang="en"><p>Sergey V. Moiseev, Cand. Sci. (Chem.), Associate Professor</p><p>8/2 Petrovsky Blvd, Moscow 127051</p></bio><email xlink:type="simple">MoiseevSV@expmed.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9133-0835</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кузьмина</surname><given-names>Н. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Kuz’mina</surname><given-names>N. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кузьмина Наталия Евгеньевна, доктор химических наук</p><p>Петровский б-р, д. 8, стр. 2, Москва, 127051</p></bio><bio xml:lang="en"><p>Natalia E. Kuz’mina, Dr. Sci. (Chem.).</p><p>8/2 Petrovsky Blvd, Moscow 127051</p></bio><email xlink:type="simple">KuzminaN@expmed.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8752-5245</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лутцева</surname><given-names>А. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Luttseva</surname><given-names>A. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Лутцева Анна Ивановна, кандидат фармацевтических наук</p><p>Петровский б-р, д. 8, стр. 2, Москва, 127051</p></bio><bio xml:lang="en"><p>Anna I. Luttseva, Cand. Sci. (Pharm.)</p><p>8/2 Petrovsky Blvd, Moscow 127051</p></bio><email xlink:type="simple">Lutceva@expmed.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Федеральное государственное бюджетное учреждение «Научный центр экспертизы средств медицинского применения» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Scientific Centre for Expert Evaluation of Medicinal Products</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2022</year></pub-date><pub-date pub-type="epub"><day>18</day><month>02</month><year>2022</year></pub-date><volume>12</volume><issue>1</issue><fpage>8</fpage><lpage>23</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Моисеев С.В., Кузьмина Н.Е., Лутцева А.И., 2022</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="ru">Моисеев С.В., Кузьмина Н.Е., Лутцева А.И.</copyright-holder><copyright-holder xml:lang="en">Moiseev S.V., Kuz’mina N.E., Luttseva A.I.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.vedomostincesmp.ru/jour/article/view/402">https://www.vedomostincesmp.ru/jour/article/view/402</self-uri><abstract><p>Изучение опыта различных национальных и мировых фармакопей в области применения метода спектроскопии ядерного магнитного резонанса (ЯМР) при контроле качества лекарственных средств актуально ввиду разработки фармакопеи Евразийского экономического союза, а также с учетом политики гармонизации отечественной и международных фармакопей. Цель работы — проведение сравнительного анализа перечня показателей качества лекарственных средств, оцениваемых методом ЯМР, в отечественной и зарубежных фармакопеях. В обзоре обобщен опыт национальных и мировых фармакопей в области применения метода ЯМР при контроле качества лекарственных средств и аттестации фармакопейных стандартных образцов. Проанализированы следующие показатели, оцениваемые данным методом: подтверждение подлинности действующего вещества, определение состава соединений нестехиометрического строения и средней длины полимерной цепи в полимерах и блок-сополимерах, определение абсолютного содержания действующего вещества в лекарственном средстве, идентификация и количественное определение примесей, полиморфизм и кристалличность. Показано, что в области внедрения метода ЯМР в фармакопейный анализ лидируют Фармакопея США и Японская фармакопея. Отмечена положительная динамика внедрения метода ЯМР в Государственной фармакопее Российской Федерации. Показана необходимость внесения изменений в общие фармакопейные статьи «Спектроскопия ядерного магнитного резонанса» и «Стандартные образцы» Государственной фармакопеи Российской Федерации XIV изд. в рамках гармонизации отечественной фармакопеи с Фармакопеей Евразийского экономического союза и Европейской фармакопеей. Эти изменения заключаются в декларировании возможности прямого способа установления подлинности вещества путем комплексного анализа спектральных данных ЯМР без сравнения спектров испытуемого и стандартных образцов. При аттестации фармакопейных стандартных образцов метод ЯМР необходимо включить в перечень абсолютных методов определения чистоты химических первичных стандартных образцов.</p></abstract><trans-abstract xml:lang="en"><p>The ongoing development of the Pharmacopoeia of the Eurasian Economic Union and the current trend for harmonisation of the Russian Pharmacopoeia with the world leading pharmacopoeias suggest the necessity of studying how different pharmacopoeias use nuclear magnetic resonance (NMR) for quality control of medicinal products. The aim of the study was to compare the extent of medicine quality characteristics assessed by NMR in the Russian and foreign pharmacopoeias. The review summarises the experience of various national and world pharmacopoeias in using the NMR method for quality control of medicines and certification of pharmacopoeial reference materials. The comparative analysis covered the following quality parameters: active ingredient identification, determination of the composition of non-stoichiometric compounds, determination of the average polymer chain length in polymers and block copolymers, determination of the absolute content of the active ingredient, identification and quantification of impurities, polymorphism, and crystallinity. It was shown that the United States and Japanese Pharmacopoeias are leading the way in introducing the NMR method into pharmacopoeial analysis. There have been some positive trends in the introduction of the NMR method in the State Pharmacopoeia of the Russian Federation as well. It was concluded that changes are needed in the general chapters “Nuclear Magnetic Resonance Spectroscopy” and “Reference Standards” of the State Pharmacopoeia of the Russian Federation, 14th ed. in order to harmonise the texts with those of the Eurasian Pharmacopoeia and the European Pharmacopoeia and to allow for the possibility of direct identification of a substance by complex analysis of NMR spectral data, without comparing the test sample and the reference standard spectra. The NMR method should be included in the list of absolute methods used for determination of purity of primary chemical reference substances during certification.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>ЯМР-спектроскопия</kwd><kwd>фармакопея</kwd><kwd>стандартный образец</kwd><kwd>фармакопейный анализ</kwd><kwd>контроль качества</kwd><kwd>лекарственное средство</kwd><kwd>гармонизация</kwd></kwd-group><kwd-group xml:lang="en"><kwd>NMR spectroscopy</kwd><kwd>pharmacopoeia</kwd><kwd>reference standard</kwd><kwd>pharmacopoeial analysis</kwd><kwd>quality control</kwd><kwd>medicinal product</kwd><kwd>harmonisation</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Работа выполнена в рамках государственного задания ФГБУ «НЦЭСМП» Минздрава России № 056-00005-21-02 на проведение прикладных научных исследований (номер государственного учета НИР 121022400083-1)</funding-statement><funding-statement xml:lang="en">The study reported in this publication was carried out as part of a publicly funded research project No. 056-00005-21-02 and was supported by the Scientific Centre for Expert Evaluation of Medicinal Products (R&amp;D public accounting No. 121022400083-1).</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Shu C-H, Wen BJ, Lin KJ. Monitoring the polysaccharide quality of Agaricus blazei in submerged culture by examining molecular weight distribution and TNF-alpha release capability of macrophage cell line RAW 264.7. Biotechnol Lett. 2004;26(4):2061–4.</mixed-citation><mixed-citation xml:lang="en">Shu C-H, Wen BJ, Lin KJ. Monitoring the polysaccharide quality of Agaricus blazei in submerged culture by examining molecular weight distribution and TNF-alpha release capability of macrophage cell line RAW 264.7. Biotechnol Lett. 2004;26(4):2061–4.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Olafsdottir ES, Omarsdottir S, Paulsen BS, Wagner H. Immunologically active O6-branched (1→3)-β-glucan from the lichen Thamnolia vermicularis var. subuliformis. Phytomedicine. 2003;10(4):318–24. https://doi.org/10.1078/094471103322004811</mixed-citation><mixed-citation xml:lang="en">Olafsdottir ES, Omarsdottir S, Paulsen BS, Wagner H. Immunologically active O6-branched (1→3)-β-glucan from the lichen Thamnolia vermicularis var. subuliformis. Phytomedicine. 2003;10(4):318–24. https://doi.org/10.1078/094471103322004811</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Cozzolino R, Malvagna P, Spina E, Giori A, Fuzzati N, Anelli A, et al. Structural analysis of the polysaccharides from Echinacea angustifolia radix. Carbohydr Polym. 2006;65(3):263–72. https://doi.org/10.1016/j.carbpol.2006.01.012</mixed-citation><mixed-citation xml:lang="en">Cozzolino R, Malvagna P, Spina E, Giori A, Fuzzati N, Anelli A, et al. Structural analysis of the polysaccharides from Echinacea angustifolia radix. Carbohydr Polym. 2006;65(3):263–72. https://doi.org/10.1016/j.carbpol.2006.01.012</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Cheng HN, Neiss TG. Solution NMR spectroscopy of food polysaccharides. Polym Rev. 2012;52(2):81–114. https://doi.org/10.1080/15583724.2012.668154</mixed-citation><mixed-citation xml:lang="en">Cheng HN, Neiss TG. Solution NMR spectroscopy of food polysaccharides. Polym Rev. 2012;52(2):81–114. https://doi.org/10.1080/15583724.2012.668154</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Westphal M, James MFM, Kozek-Langenecker S, Stocker R, Guidet B, Van Aken H. Hydroxyethyl starches: different products — different effects. Anesthesiology. 2009;111(1):187–202. https://doi.org/10.1097/ALN.0b013e3181a7ec82</mixed-citation><mixed-citation xml:lang="en">Westphal M, James MFM, Kozek-Langenecker S, Stocker R, Guidet B, Van Aken H. Hydroxyethyl starches: different products — different effects. Anesthesiology. 2009;111(1):187–202. https://doi.org/10.1097/ALN.0b013e3181a7ec82</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Yuruk K, Almac E, Ince C. Hydroxyethyl starch solutions and their effect on the microcirculation and tissue oxygenation. Transfus Altern Transfus Med. 2007;3(9):164–72. https://doi.org/10.1111/j.1778-428X.2007.00076.x</mixed-citation><mixed-citation xml:lang="en">Yuruk K, Almac E, Ince C. Hydroxyethyl starch solutions and their effect on the microcirculation and tissue oxygenation. Transfus Altern Transfus Med. 2007;3(9):164–72. https://doi.org/10.1111/j.1778-428X.2007.00076.x</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Lane DA, Lindahl U, eds. Heparin: chemical and biological properties. In: Clinical applications. Boca Raton, Florida: CRC Press; 1989.</mixed-citation><mixed-citation xml:lang="en">Lane DA, Lindahl U, eds. Heparin: chemical and biological properties. In: Clinical applications. Boca Raton, Florida: CRC Press; 1989.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Guerrini M, Becatti D, Shriver Z, Naggi A, Viswanathan K, Bisio A, et al. Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events. Nat Biotechnol. 2008;26(6):669–75. https://doi.org/10.1038/nbt1407</mixed-citation><mixed-citation xml:lang="en">Guerrini M, Becatti D, Shriver Z, Naggi A, Viswanathan K, Bisio A, et al. Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events. Nat Biotechnol. 2008;26(6):669–75. https://doi.org/10.1038/nbt1407</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Kishimoto TK, Viswanathan K, Ganguly T, Elankumaran S, Smith S, Pelzer K, et al. Contaminated heparin associated with adverse clinical events and activation of the contact system. N Engl J Med. 2008;358(23):2457– 67. https://doi.org/10.1056/nejmoa0803200</mixed-citation><mixed-citation xml:lang="en">Kishimoto TK, Viswanathan K, Ganguly T, Elankumaran S, Smith S, Pelzer K, et al. Contaminated heparin associated with adverse clinical events and activation of the contact system. N Engl J Med. 2008;358(23):2457– 67. https://doi.org/10.1056/nejmoa0803200</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Censi R, Di Martino P. Polymorph impact on the bioavailability and stability of poorly soluble drugs. Molecules. 2015;20(10):18759–76. https://doi.org/10.3390/molecules201018759</mixed-citation><mixed-citation xml:lang="en">Censi R, Di Martino P. Polymorph impact on the bioavailability and stability of poorly soluble drugs. Molecules. 2015;20(10):18759–76. https://doi.org/10.3390/molecules201018759</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Singhal D, Curatolo W. Drug polymorphism and dosage form design: a practical perspective. Adv Drug Deliv Rev. 2004;56(3):335–47. https://doi.org/10.1016/j.addr.2003.10.008</mixed-citation><mixed-citation xml:lang="en">Singhal D, Curatolo W. Drug polymorphism and dosage form design: a practical perspective. Adv Drug Deliv Rev. 2004;56(3):335–47. https://doi.org/10.1016/j.addr.2003.10.008</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Zhou Y, Wang J, Xiao Y, Wang T, Huang X. The effects of polymorphism on physicochemical properties and pharmacodynamics of solid drugs. Curr Pharm Des. 2018;24(21):2375–82. https://doi.org/10.2174/1381612824666180515155425</mixed-citation><mixed-citation xml:lang="en">Zhou Y, Wang J, Xiao Y, Wang T, Huang X. The effects of polymorphism on physicochemical properties and pharmacodynamics of solid drugs. Curr Pharm Des. 2018;24(21):2375–82. https://doi.org/10.2174/1381612824666180515155425</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Смирнова ИГ, Гильдеева ГН, Чистяков ВВ. Анализ кристаллической и пространственной структуры лекарственных веществ. Вестник Московского университета. Серия 2: Химия. 2012;53(4):234–40.</mixed-citation><mixed-citation xml:lang="en">Smirnova IG, Gildeeva GN, Chistyakov VV. Analysis of crystalline structure and chirality of drug substances. Vestnik Moskovskogo universiteta. Seriya 2: Khimiya = Moscow University Chemistry Bulletin. 2012;53(4):234–40 (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Brittain HG, ed. Polymorphism in pharmaceutical solids. New York: Marcel Dekker; 1999.</mixed-citation><mixed-citation xml:lang="en">Brittain HG, ed. Polymorphism in pharmaceutical solids. New York: Marcel Dekker; 1999.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Desiraju GR. Supramolecular synthons in crystal engineering — a new organic synthesis. Angew Chem Int Ed Engl. 1995;34(21):2311–27. https://doi.org/10.1002/anie.199523111</mixed-citation><mixed-citation xml:lang="en">Desiraju GR. Supramolecular synthons in crystal engineering — a new organic synthesis. Angew Chem Int Ed Engl. 1995;34(21):2311–27. https://doi.org/10.1002/anie.199523111</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Reddy DS, Ovchinnikov YE, Shishkin OV, Struchkov YT, Desiraju GR. Supramolecular synthons in crystal engineering. 3. Solid state architecture and synthon robustness in some 2,3-dicyano-5,6-dichloro-1,4-dialkoxybenzenes. J Am Chem Soc. 1996;118(17):4085–9. https://doi.org/10.1021/ja953372u</mixed-citation><mixed-citation xml:lang="en">Reddy DS, Ovchinnikov YE, Shishkin OV, Struchkov YT, Desiraju GR. Supramolecular synthons in crystal engineering. 3. Solid state architecture and synthon robustness in some 2,3-dicyano-5,6-dichloro-1,4-dialkoxybenzenes. J Am Chem Soc. 1996;118(17):4085–9. https://doi.org/10.1021/ja953372u</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Serezhkin VN, Serezhkina LB. New criterion for conformational polymorphism. Crystallogr Rep. 2012;57(1):33– 42. https://doi.org/10.1134/S1063774511030291</mixed-citation><mixed-citation xml:lang="en">Serezhkin VN, Serezhkina LB. New criterion for conformational polymorphism. Crystallogr Rep. 2012;57(1):33– 42. https://doi.org/10.1134/S1063774511030291</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Кузьмина НЕ, Моисеев СВ, Яшкир ВА, Осинцева ЕВ. Возможности использования метода ядерного магнитного резонанса при аттестации стандартных образцов. Стандартные образцы. 2014;(2):19–25.</mixed-citation><mixed-citation xml:lang="en">Kuz’mina NE, Moiseev SV, Yashkir VA, Osintseva EV. The possibility of the nuclear magnetic resonance methods using for reference standards certification. Standartnye obraztsy = Reference Materials. 2014;(2):19–25 (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Кузьмина НЕ, Моисеев СВ, Крылов ВИ, Яшкир ВА, Меркулов ВА. Валидация методики определения молярного замещения гидроксиэтилкрахмалов методом 1 Н ЯМР-спектроскопии. Химико-фармацевтический журнал. 2016;50(4):47–51. https://doi.org/10.30906/0023-1134-2016-50-4-47-51 https://doi.org/10.1007/s11094-016-1435-9</mixed-citation><mixed-citation xml:lang="en">Kuz’mina NE, Moiseev SV, Krylov VI, Yashkir VA, Merkulov VA. Validation of a method for measuring the molar substitution of hydroxyethylstarches by 1 H NMR Spectroscopy. Pharmaceutical Chemistry Journal. 2016;50(4):265–9] https://doi.org/10.1007/s11094-016-1435-9</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Кузьмина НЕ, Моисеев СВ, Крылов ВИ, Кутин АА, Жуков ЕА, Яшкир ВА, Меркулов ВА. Валидация методики определения аминокислотного состава фармацевтической субстанции «Глатирамера ацетат» методом 13 C ЯМР-спектроскопии. Ведомости Научного центра экспертизы средств медицинского применения. 2017;7(3):175–81.</mixed-citation><mixed-citation xml:lang="en">Kuz’mina NE, Moiseev SV, Krylov VI, Kutin AA, Zhukov EA, Yashkir VA, Merkulov VA. Validation of the procedure for determination of amino acids composition of glatiramer acetate by C-13 NMR spectroscopy. Vedomosti Nauchnogo tsentra ekspertizy sredstv meditsinskogo primeneniya = Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. 2017;7(3):175–81 (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Моисеев СВ, Кузьмина НЕ, Крылов ВИ, Яшкир ВА, Меркулов ВА. Валидация методики определения средней молекулярной массы декстранов методом диффузионно-упорядоченной спектроскопии. Химико-фармацевтический журнал. 2017;51(9):60–3. https://doi.org/10.30906/0023-1134-2017-51-9-60-63</mixed-citation><mixed-citation xml:lang="en">Moiseev SV, Kuz’mina NE, Krylov VI, Yashkir VA, Merkulov VA. Validation of a method of measuring mean molecular weight of dextrans by diffusion-ordered spectroscopy. Pharmaceutical Chemistry Journal. 2017;51(9):829–32 https://doi.org/10.1007/s11094-017-1701-5</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Кузьмина НЕ, Моисеев СВ, Крылов ВИ, Дерябин АС, Яшкир ВА, Меркулов ВА. Валидация методики подтверждения подлинности фармацевтической субстанции «Бусерелина ацетат» методом ЯМР-спектроскопии. Химико-фармацевтический журнал. 2018;52(2):48–53. https://doi.org/10.30906/0023-1134-2018-52-2-48-53</mixed-citation><mixed-citation xml:lang="en">Kuz’mina NE, Moiseev SV, Krylov VI, Deryabin AS, Yashkir VA, Merkulov VA. Validation of an NMR-spectroscopic method for authenticity confirmation of buserelin acetate pharmaceutical substance. Pharmaceutical Chemistry Journal. 2018;52(2):159–65 https://doi.org/10.1007/s11094-018-1783-8</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Моисеев СВ, Кузьмина НЕ, Крылов ВИ, Яшкир ВА, Меркулов ВА. Валидация методики количественного определения трифторацетатов в фармацевтической субстанции «глатирамера ацетат» методом 19 F ЯМР-спектроскопии. Химико-фармацевтический журнал. 2018;52(7):61–4. https://doi.org/10.30906/0023-1134-2018-52-7-61-64</mixed-citation><mixed-citation xml:lang="en">Moiseev SV, Kuz’mina NE, Krylov VI, Yashkir VA, Merkulov VA. Validation of a method for assay of trifluoroacetates in the pharmaceutical substance glatiramer acetate by 19 F NMR spectroscopy. Pharmaceutical Chemistry Journal. 2018;52(7):658–62 https://doi.org/10.1007/s11094-018-1877-3</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Моисеев СВ, Кузьмина НЕ, Лутцева АИ. Разработка методик подтверждения подлинности фармацевтических субстанций трипторелина ацетат и гозерелина ацетат методом ЯМР-спектроскопии. Ведомости Научного центра экспертизы средств медицинского применения. 2019;9(1):54– 63. https://doi.org/10.30895/1991-2919-2019-9-1-54-63</mixed-citation><mixed-citation xml:lang="en">Moiseev SV, Kuz’mina NE, Luttseva AI. Development of identification test methods for triptorelin acetate and goserelin acetate substances using NMR spectroscopy. Vedomosti Nauchnogo tsentra ekspertizy sredstv meditsinskogo primeneniya = Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. 2019;9(1):54–63 (In Russ.)] https://doi.org/10.30895/1991-2919-2019-9-1-54-63</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Kuz’mina NE, Moiseev SV, Khorolskiy MD, Lutceva AI. Development and validation of 2-azaspiro [4,5] decan-3-one (impurity A) in gabapentin determination method using qNMR spectroscopy. Molecules. 2021;26(6):1656. https://doi.org/10.3390/molecules26061656</mixed-citation><mixed-citation xml:lang="en">Kuz’mina NE, Moiseev SV, Khorolskiy MD, Lutceva AI. Development and validation of 2-azaspiro [4,5] decan-3-one (impurity A) in gabapentin determination method using qNMR spectroscopy. Molecules. 2021;26(6):1656. https://doi.org/10.3390/molecules26061656</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
